Dosar de subiect
HSBC Downgrades Lilly Stock Ahead of Expected Weight Loss Drug Price Cuts
Primul articol: 17 mar. 2026, 15:59
|
Ultima actualizare: 17 mar. 2026, 15:59
|
1 sursa
|
1 articol
Mai multe surse. Mai putina manipulare.
Analiza editoriala
Bazat pe 1 sursa, 1 articol
HSBC has issued a "sell" rating for Eli Lilly (Lilly) stock, citing expectations of significant price reductions for its weight loss medications. The downgrade reflects concerns that these price cuts will negatively impact Lilly's revenue streams and overall profitability. The move highlights the competitive pressures within the weight loss drug market and the challenges pharmaceutical companies face in balancing pricing with market access.Articole despre acest subiect
Foto: Bloomberg
Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts
Eli Lilly & Co. shares dip after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are over inflated.
Citeste pe Bloomberg →